BioSig Technologies Gestione

Gestione criteri di controllo 0/4

BioSig Technologies Il CEO è Anthony Amato, nominato in Apr2024, ha un mandato di meno di un anno. possiede direttamente 4.86% delle azioni della società, per un valore di $ 1.54M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 0.6 anni e 1.7 anni.

Informazioni chiave

Anthony Amato

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	4.9%
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	1.7yrs

Aggiornamenti recenti sulla gestione

Shareholders May Be More Conservative With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation For Now

Dec 12

Recent updates

Shareholders May Be More Conservative With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation For Now

Dec 12

Shareholders May Not Be So Generous With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation And Here's Why

Dec 14

AMMINISTRATORE DELEGATO

Anthony Amato (56 yo)

less than a year

Mandato

Mr. Anthony Amato served as Member of Advisory Board at BioSig Technologies, Inc. from January 2021 to February 2024 and serves as its CEO & Chairman since April 30, 2024. He has corporate expertise in the...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Anthony Amato	CEO & Chairman	less than a year	Nessun dato	4.86% $ 1.5m
Ferdinand Groenewald	Interim CFO & Principal Accounting Officer	less than a year	Nessun dato	Nessun dato
Budimir Drakulic	Chief Scientist	15.8yrs	US$243.75k	Nessun dato
Lora Mikolaitis	Chief Administrative Officer	no data	US$96.00k	Nessun dato

0.6yrs

Durata media

53.5yo

Età media

Gestione esperta: Il team dirigenziale di BSGM non è considerato esperto (durata media 0.6 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Anthony Amato	CEO & Chairman	less than a year	Nessun dato	4.86% $ 1.5m
Zachariah Zachariah	Member of Advisory Board	4.7yrs	Nessun dato	Nessun dato
Lorraine Spurge	Member of Advisory Board	1.7yrs	Nessun dato	Nessun dato
Edwin Wang	Member of Advisory Board	1.7yrs	Nessun dato	Nessun dato
Frederick Hrkac	Director	less than a year	US$701.58k	3.82% $ 1.2m
Sim Farar	Member of Advisory Board	6.5yrs	Nessun dato	Nessun dato
Ramachandra Malya	Member of Advisory Board	6.7yrs	Nessun dato	Nessun dato
Frank Quintero	Member of Advisory Board	5.6yrs	Nessun dato	Nessun dato
Christopher Baer	Independent Director	less than a year	Nessun dato	0.47% $ 148.0k
Steven Abelman	Independent Director	less than a year	Nessun dato	0.47% $ 148.0k
Donald Browne	Independent Director	less than a year	Nessun dato	0.47% $ 148.0k

1.7yrs

Durata media

62.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di BSGM non è considerato esperto (durata media del mandato 1.7 anni), il che suggerisce un nuovo consiglio.

BioSig Technologies Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

BioSig Technologies, Inc., Annual General Meeting, Dec 31, 2024

BioSig Technologies, Inc. Appoints Anthony Amato as Chief Executive Officer

Biosig Technologies, Inc. Announces Resignation of Kenneth L. Londoner as Chief Executive Officer

Shareholders May Be More Conservative With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation For Now

Biosig Technologies, Inc. Appoints Fred Hrkac as Executive Vice President

BioSig Technologies, Inc., Annual General Meeting, Dec 18, 2023

Recent updates

BioSig Technologies, Inc., Annual General Meeting, Dec 31, 2024

BioSig Technologies' Common Stock Deleted from OTC Equity

Nasdaq Hearings Panel Determines to Delist BioSig Technologies' Common Stock

BioSig Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $3.000005 million.

BioSig Technologies, Inc. announced delayed 10-Q filing

BioSig Technologies Regains Compliance with the Minimum Bid Price Requirements in Listing Rule 5550(a)(2)

BioSig Technologies, Inc. Appoints Anthony Amato as Chief Executive Officer

BioSig Technologies, Inc. announced delayed annual 10-K filing

BioSig Technologies Receives Letter from Nasdaq Regarding No Longer Meets the Requirement of Rule 5550(b)(2)

BioSig Technologies Receives a Letter from the Listing Qualifications Department of Nasdaq Stating That the Company Has Not Regained Compliance with the Rule

Biosig Technologies, Inc. Announces Resignation of Kenneth L. Londoner as Chief Executive Officer

BioSig Announces Reduction of its Workforce

Biosig Technologies, Inc. Commences Workforce Reduction Consisted of the Departure of Sixteen Employees

BioSig Technologies, Inc. announced that it expects to receive $1.04 million in funding

BioSig Technologies Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Market Value of Listed Securities

Consensus revenue estimates decrease by 67%, EPS upgraded

Shareholders May Be More Conservative With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation For Now

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

BioSig Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $2.5 million.

BioSig Technologies, Inc. has filed a Follow-on Equity Offering.

BioSig Technologies, Inc. has filed a Follow-on Equity Offering.

Biosig Technologies, Inc. Appoints Fred Hrkac as Executive Vice President

BioSig Technologies, Inc., Annual General Meeting, Dec 18, 2023

BioSig Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $0.13464 million.

BioSig Technologies, Inc. announced that it has received $0.597497 million in funding

Price target increased by 27% to US$5.63

Consensus revenue estimates decrease by 24%

BioSig Technologies, Inc. announced that it has received $0.549999 million in funding

BioSig Technologies, Inc. Achieves Infrastructure and Technology Progress in Development of Generative AI Platform for Hospitals

Biosig Technologies, Inc. Introduces New Subscription Model for Pure Ep™ Platform, Offering Quicker Access to Latest Features, Customers

Biosig Technologies, Inc.'s Pure Ep Platform Debuts New Automated Features in First Patient Cases

Second quarter 2023 earnings released: US$0.16 loss per share (vs US$0.15 loss in 2Q 2022)

New minor risk - Share price stability

BioSig Technologies, Inc. Advances Collaboration on Machine Learning and Artificial Intelligence Solutions for Healthcare

Price target increased by 8.0% to US$4.50

Consensus EPS estimates fall by 24%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 65%, EPS upgraded

BioSig Technologies, Inc. Announces Chief Financial Officer Changes

BioSig Technologies, Inc. announced that it has received $1.299999 million in funding

BioSig Technologies, Inc. announced that it expects to receive $0.159998 million in funding

BioSig Technologies, Inc. announced that it expects to receive $1.299999 million in funding

BioSig's PURE EP(TM) System Demonstrates Potential Time and Cost Savings At the 15th APHRS Scientific Session in Singapore

Shareholders May Not Be So Generous With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation And Here's Why

BioSig Technologies Receives a Letter from the Nasdaq Stock Market

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$4.17

BioSig Technologies, Inc., Annual General Meeting, Dec 20, 2022

BioSig Technologies Receives Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price

BioSig in acquisition pact with San Antonio Hospital for cardiac signal system

BioSig Technologies, Inc. Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module

BioSig: No Changes To Hold Thesis Following Q2 Earnings

Consensus forecasts updated

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

BioSig Technologies Receives Non-Compliance Letter from Nasdaq

Consensus revenue estimates fall by 55%

BioSig signs purchase deal with Kansas City's Overland Park Regional hospital

BioSig: PURE EP Economics Trade Exhausted

BioSig Technologies, Inc.’s PURE EP™ System to be Featured During EPLive 2022

Consensus revenue estimates fall by 18%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$8.50

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione